Biomarin Pharmaceutical Inc (NASDAQ: BMRN) has a price-to-earnings ratio that is above its average at 20.85x. The stock has a 36-month beta value of 0.17. Opinions on the stock are mixed, with 16 analysts rating it as a “buy,” 7 as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for BMRN is 189.06M, and at present, short sellers hold a 2.34% of that float. On July 02, 2025, the average trading volume of BMRN was 2.13M shares.
BMRN) stock’s latest price update
Biomarin Pharmaceutical Inc (NASDAQ: BMRN)’s stock price has plunge by 2.22relation to previous closing price of 54.97. Nevertheless, the company has seen a 2.74% surge in its stock price over the last five trading sessions. prnewswire.com reported 2025-07-01 that SAN RAFAEL, Calif., July 1, 2025 /PRNewswire/ — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (Nasdaq: INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million.
BMRN’s Market Performance
Biomarin Pharmaceutical Inc (BMRN) has seen a 2.74% rise in stock performance for the week, with a -3.24% decline in the past month and a -20.51% plunge in the past quarter. The volatility ratio for the week is 2.29%, and the volatility levels for the past 30 days are at 2.51% for BMRN. The simple moving average for the past 20 days is 0.82% for BMRN’s stock, with a -13.37% simple moving average for the past 200 days.
Analysts’ Opinion of BMRN
Many brokerage firms have already submitted their reports for BMRN stocks, with Oppenheimer repeating the rating for BMRN by listing it as a “Outperform.” The predicted price for BMRN in the upcoming period, according to Oppenheimer is $98 based on the research report published on February 24, 2025 of the current year 2025.
Wolfe Research, on the other hand, stated in their research note that they expect to see BMRN reach a price target of $95. The rating they have provided for BMRN stocks is “Outperform” according to the report published on November 15th, 2024.
BMRN Trading at -3.71% from the 50-Day Moving Average
After a stumble in the market that brought BMRN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.76% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BMRN starting from Burkhart Erin, who sale 1,786 shares at the price of $59.31 back on May 20 ’25. After this action, Burkhart Erin now owns 14,173 shares of Biomarin Pharmaceutical Inc, valued at $105,928 using the latest closing price.
Stock Fundamentals for BMRN
Current profitability levels for the company are sitting at:
- 0.21 for the present operating margin
- 0.79 for the gross margin
The net margin for Biomarin Pharmaceutical Inc stands at 0.18. The total capital return value is set at 0.09. Equity return is now at value 9.64, with 7.47 for asset returns.
Based on Biomarin Pharmaceutical Inc (BMRN), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at 1.18. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is 96.33.
Currently, EBITDA for the company is 650.86 million with net debt to EBITDA at -0.61. When we switch over and look at the enterprise to sales, we see a ratio of 3.51. The receivables turnover for the company is 3.97for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.52.
Conclusion
To sum up, Biomarin Pharmaceutical Inc (BMRN) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
